Loading…
Loading…
RAFA does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for RAFA and 80,000+ other tickers.
See exactly how RAFA's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for RAFA and 80,000+ other tickers.
Rafarma Pharmaceuticals, Inc. is a diversified pharmaceutical enterprise that manufactures and distributes a range of medicinal products, including generic antibiotics and specialized drugs, within the Russian market. Its product portfolio encompasses anti-cancer medications, cephalosporin-derived compounds, and non-beta-lactam antibiotics. These are available in various formats such as injectable solutions, ampoules, pediatric suspensions, oral tablets, and capsules. Additionally, Rafarma develops and supplies treatments for injuries, ocular inflammatory conditions, and immunological…
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com
Sheridan, Wyoming, USA, July 04, 2024 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA) - Rafarma Pharmaceuticals is pleased to announce its participation in the scientific conference on radioembolization using Yttrium 90 microspheres for the treatment of cancer at Severance Hospital in Seoul, South Korea. It is one of the largest university hospitals in South Korea and is of strategic importance to the country.
Sheridan, Wyoming, USA, July 03, 2024 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA) - Rafarma Pharmaceuticals is pleased to announce the signing of a preliminary agreement to establish a joint industrial venture in Busan Technology Park (South Korea) as the Dongnam Industrial Park of Radiological & Medical Sciences. The partners in the venture are Rafarma and the Korean pharmaceutical company Woods Medical Care.
Wyoming, USA, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA) - We are pleased to announce that Rapharma and its CEO Raivo Unt have entered into a preliminary agreement with Kelun Lifesciences (Pvt) Ltd, a pharmaceutical company based in Sri Lanka, on 17 November 2023. It is Sri Lanka's first and only pharmaceutical manufacturing facility for sterile liquid injections and infusions. The headquarters of the company is based in Kandy on the island of Sri Lanka.
Russia, Moscow, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals (OTC: RAFA). The Company is pleased to announce that it has completed the restructuring, accounting and balance sheet procedures required to comply with GAAP auditing standards.